Fig. 1.
Comparison of drug development approaches. Drug development is currently an extraordinarily costly endeavor with a very low success rate, much of which can be attributed to incorrect therapeutic hypotheses based on preclinical models that do not accurately predict human biology.21 The ADDRI's work fits within the new paradigm of drug development, which holds the promise of improved time and cost efficiency compared with the traditional approach. Human data drive the entire process in the new paradigm, and this should lead to a higher likelihood of success. ADDRI, Accelerating Drug Development and Repurposing Incubator.